The launch makes all the approved strengths of the reformulated version product including 5mg, 7.5mg, 10mg, 15mg, 20mg, 30mg and 40mg available to patients.
Endo Health Solutions chief operating officer Julie McHugh said, "Considering that a substantial amount of abuse and misuse of opioid products is performed by manipulating the tablet through crushing and powdering, we are excited to offer patients and healthcare professionals a full line of strength options of the reformulated, designed to be crush-resistant, OPANA ER."
In conjunction with the launch, the company also filed a false advertising suit against Actavis asking it to discontinue promoting its non-crush-resistant extended release oxymorphone HCl product as bio-equivalent, to the reformulated OPANA ER.